DeepMed Research

West China Hospital of Sichuan University (Sichuan International Hospital)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Application of the Propofol Precise Infusion Model

Completed

Conditions: Propofol Overdose of Undetermined Intent

Interventions: Drug: Propofol

First Posted Date: 2021-12-15

Last Posted Date: 2021-12-15

Lead Sponsor: West China Hospital

Target Recruit Count: 400

Registration Number: NCT05158426

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

Phase 2

Conditions: Prostatic Neoplasms, Castration-Resistant
Drug Therapy, Combination

Interventions: Drug: TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone

First Posted Date: 2021-12-14

Last Posted Date: 2021-12-14

Lead Sponsor: West China Hospital

Target Recruit Count: 30

Registration Number: NCT05156450

Locations: 🇨🇳
West China Hospital, Chengdu, Sichuan, China

Brain Lesions After Transcatheter Aortic Valve Replacement

Conditions: Aortic Valve Stenosis
Brain Diseases

Interventions: Other: Brain MRI

First Posted Date: 2021-10-04

Last Posted Date: 2022-01-13

Lead Sponsor: West China Hospital

Target Recruit Count: 150

Registration Number: NCT05065697

ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure

Not Applicable

Completed

Conditions: Analgesia
Pectus Excavatum
Nerve Block

Interventions: Procedure: ESPB group
Procedure: TPVB group

First Posted Date: 2021-09-05

Last Posted Date: 2023-11-18

Lead Sponsor: West China Hospital

Target Recruit Count: 68

Registration Number: NCT05034601

Locations: 🇨🇳
Department of Anesthesiology, West China Hospital, Chengdu, Sichuan, China

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

Phase 2

Recruiting

Conditions: Colo-rectal Cancer
Cetuximab
Capecitabine

Interventions: Drug: mFOLFOX6 plus cetuximab
Drug: mCapOX plus cetuximab

First Posted Date: 2021-08-26

Last Posted Date: 2024-03-07

Lead Sponsor: West China Hospital

Target Recruit Count: 150

Registration Number: NCT05022030

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Phase 1

Conditions: Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Interventions: Drug: Vemurafenib Oral Tablet [Zelboraf]
Drug: Cetuximab Injection [Erbitux]
Drug: Camrelizumab

First Posted Date: 2021-08-25

Last Posted Date: 2022-05-19

Lead Sponsor: West China Hospital

Target Recruit Count: 12

Registration Number: NCT05019534

Locations: 🇨🇳
Sichuan University West China Hospital, Chengdu, Sichuan, China

FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer

Phase 2

Conditions: FOLFOXIRI Regimen
High-risk Locally Advanced Colorectal Cancer
Neoadjuvant Chemotherapy

Interventions: Drug: Oxaliplatin
Drug: Irinotecan
Drug: Folinic Acid
Drug: 5FU
Drug: Capecitabine

First Posted Date: 2021-08-24

Last Posted Date: 2021-08-24

Lead Sponsor: West China Hospital

Target Recruit Count: 69

Registration Number: NCT05018182

Locations: 🇨🇳
Sichuan University West China Hospital, Chengdu, Sichuan, China

Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)

Not Applicable

Conditions: Kidney Transplantation
Metabolic Disorder
Empagliflozin
Metformin

Interventions: Drug: SGLT2 inhibitor
Other: Placebo
Drug: Metformin

First Posted Date: 2021-08-19

Last Posted Date: 2021-08-19

Lead Sponsor: West China Hospital

Target Recruit Count: 105

Registration Number: NCT05013112

Safety and Immunogenicity of 2-dose Inactivated COVID-19 Vaccine in Kidney Transplant Recipients

Conditions: Kidney Transplantation
SARS-CoV-2 Acute Respiratory Disease
Vaccine

First Posted Date: 2021-07-20

Last Posted Date: 2021-07-20

Lead Sponsor: West China Hospital

Target Recruit Count: 300

Registration Number: NCT04969614

β-hydroxy-β-methylbutyrate-enriched Nutritional Supplements for Obesity Adults

Not Applicable

Conditions: Obesity

Interventions: Dietary Supplement: Placebo
Dietary Supplement: HMB-enriched Nutritional Supplements
Behavioral: Caloric Restrition Diet

First Posted Date: 2021-07-08

Last Posted Date: 2021-09-14

Lead Sponsor: West China Hospital

Target Recruit Count: 72

Registration Number: NCT04953936

Locations: 🇨🇳
West China Hospital，Sichuan University, Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy